|
For this year’s Annual Conference, NECA invited Professor. David Haslam the current chair of NICE (National Institute for Health and Care Excellence) to deliver a key note speech on HTA in the United Kingdom. He started his speech with the background of NICE’ s establishment, the controversies with post code prescribing and the slow introduction of new technologies and practices. How the organization grew its influence expanding its scope over the past 15 years. He explained what a NICE guidance was, and the various groups (Users, professionals, politicians, the public, media and academia) who actively participate in the development. He explained the organization structure of NICE especially putting an emphasis on the Centre for Health Technology Evaluation (CHTE) which mainly conducts technology appraisals. He also spoke about the appraisals team, and how the topic is selected for technology appraisal, the pro cesses of the 1st and the 2nd appraisal committee meeting. In addition, he covered the difference between a Single Technology Appraisal(STA) and a Multiple Technology Appraisal (MTA). The Appeals process was also covered, the grounds of appeals and how the numbers of appraisals requesting the appeals process have decreased over the years. Due to the fact that most appraisals are based on new drug appl ications, he explained about the economic evaluation of new drugs. Also the Patient Access Schemes for drugs rejected by NICE with a threshold exceeding 30,000/QALY. He closed the presentation of how the perception of NICE has positively transformed compared with 1999.
|